Filing Details

Accession Number:
0001645113-22-000020
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-07 18:23:57
Reporting Period:
2022-03-03
Accepted Time:
2022-03-07 18:23:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1645113 Novocure Ltd NVCR Surgical & Medical Instruments & Apparatus (3841) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744884 Pritesh Shah C/O Novocure Inc.,
20 Valley Stream Parkway, Suite 300
Malvern PA 19355
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2022-03-03 21,714 $0.00 95,226 No 4 A Direct
Ordinary Shares Disposition 2022-03-03 997 $74.50 94,229 No 4 S Direct
Ordinary Shares Disposition 2022-03-04 2,632 $73.34 91,597 No 4 S Direct
Ordinary Shares Disposition 2022-03-04 1,914 $70.41 89,683 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Options to Buy Ordinary Shares Acquisiton 2022-03-03 38,027 $80.59 38,027 $80.59
Ordinary Shares Options to Buy Ordinary Shares Acquisiton 2022-03-03 6,231 $80.59 6,231 $80.59
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
38,027 2023-03-01 2032-02-29 No 4 A Direct
6,231 2023-03-01 2032-02-29 No 4 A Direct
Footnotes
  1. Represents restricted share units that are scheduled to vest in equal installments on each of March 21, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
  2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  3. Options to buy 38,027 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
  4. Options to buy 6,231 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.